Anti-CD19 Recombinant Antibody Products

Loading...

Anti-CD19 Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.

Creative Biolabs offers cutting-edge recombinant antibodies targeting CD19, designed to support and advance biomedical research. Leveraging our advanced platforms, we ensure that each product adheres to the highest quality and performance standards. Our extensive portfolio of recombinant products is crafted to deliver exceptional value and reliability. In addition to our high-quality antibodies, we are committed to providing outstanding technical support, assisting researchers at every phase of their projects. Partnering with Creative Biolabs means gaining access to innovative solutions and a dedicated ally in your scientific journey.

CD19: A Key Target in B Cell Malignancies and Immunotherapy

CD19 is a cell surface protein predominantly expressed on B cells and plays a crucial role in B cell development and activation. It has become an important therapeutic target, particularly in B cell-related malignancies like chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin lymphoma (NHL). The targeting of CD19 is a promising strategy in immunotherapy, especially with CAR-T cell therapies, where genetically modified T cells are engineered to specifically recognize and kill CD19-positive B cells. CD19's restricted expression to B cells makes it an ideal target for selective treatment, minimizing off-target effects. Furthermore, the advent of monoclonal antibodies targeting CD19 has led to significant advances in treating diseases like CLL and diffuse large B-cell lymphoma. However, challenges remain, such as the development of resistance and the potential for targeting normal B cells, which may cause immune deficiencies. Despite these hurdles, CD19 continues to be a central focus in the development of innovative treatments for hematological malignancies.

Alternative Names

Complement CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; B-Lymphocyte Antigen CD19; CVID3; B4

Background

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections.

Anti-CD19 rAb Products

We are dedicated to accelerating research and advancing scientific discoveries by providing premium anti-CD19 recombinant antibody products. Our offerings are not only of exceptional quality but also deliver outstanding value. In addition, we back our products with comprehensive technical support, ensuring researchers have the resources they need to succeed at every stage of their work. Through our commitment to excellence, we aim to be a trusted partner in driving forward cutting-edge research in immunology and related fields.

Creative Quality Control

We are dedicated to advancing biopharmaceutical research and development through to commercialization, with a strong emphasis on customer satisfaction. Our core values center on delivering top-tier product quality to meet the specific needs of our clients. To ensure the highest standards, we have implemented a robust quality management system. By consistently exceeding customer expectations, we aim to streamline the drug development process, helping our clients save valuable time.

Customer Reviews

Excellent

J**on
Anti-Human CD19 Recombinant Antibody (CAT#: TAB-431CQ)

This is a reliable tool for research involving B cells. It works well in applications like IHC and WB. This antibody specifically targets human CD19, making it useful for studying B-cell-related processes and disorders. It has shown effectiveness in tissues such as human peripheral blood B cells, lymph nodes, and bone marrow. Researchers have found it to provide clear and consistent results in detecting CD19 expression, without non-specific binding issues. Overall, this antibody is a practical option for anyone studying B-cell biology or related diseases.

16/Apr/2023

Excellent

C**er
Human Anti-CD19 Recombinant Antibody (HPAB-0418LY) (CAT#: HPAB-0418LY)

It has proven to be a useful reagent for B cell research. It has been validated on B cell lines, ensuring strong specificity for CD19 detection. The antibody works well in ELISA, FC, and other applications like Western blotting, making it versatile for various experimental needs. It effectively identifies CD19 expression in B cells, offering consistent and reproducible results. While the antibody performs well in standard assays, slight adjustments may be needed depending on experimental setup. Overall, HPAB-0418LY is a practical and reliable choice for those working in immunology and hematology research.

10/Jul/2023

Excellent

G**ia
Anti-Human CD19 Recombinant Antibody (TAB-108CL) (CAT#: TAB-108CL)

This product works effectively for detecting CD19 on human B cell lines, ensuring reliable specificity. It performs well in FC and FuncS, providing consistent results. Researchers have successfully used it to examine B cell activation and signaling. While it generally delivers good performance, some optimization may be required depending on the experimental conditions. Overall, TAB-108CL is a dependable antibody for studying B cells and their role in immunology and related fields.

18/Sep/2021

rAb Production

With years of experience in recombinant antibody production and optimization, we pride ourselves on offering exceptional service and delivering high-quality recombinant antibodies within the shortest possible time. Our commitment is to ensure that each product meets the highest standards of excellence.

Featured Anti-CD19 Recombinant Antibody Production Platforms
Fig.4 Milligram-scale recombinant antibody production.

Fig.5 Gram-scale recombinant antibody production.

rAb Modalities

Creative Biolabs is committed to providing researchers with a comprehensive selection of cutting-edge, high-quality recombinant antibodies in diverse formats. Our expertise in antibody engineering spans a variety of advanced techniques, and we offer exceptional custom engineering services to meet your unique requirements.

Fig.6 Full Length Anti-CD19 Recombinant Antibody Production and Modalities.

Drug Information Targeting CD19

Table 1. Therapeutic approaches targeting CD19 in clinical development.

If you need further details about the CD19 target, don't hesitate to contact us by phone or email. Our expert team is always ready to provide assistance and answer any questions you may have, offering the support you need to ensure the success of your research.

Related Diseases

Primary Immunodeficiency